This pilot study randomly assigned patients to receive one of two triple-drug regimens (stavudine, didanosine, and efavirenz
or zidovudine, lamivudine, and nelfinavir) or to alternate between the two regimens every 3 months. Alternating the regimens
delayed virologic failure.